Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 22-26, 2022 in Washington, D.C.

“We are excited to have such a large presence at this year’s ASCRS which we believe highlights the interest in DEXTENZA^® as well as our other ocular surface programs,” commented Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix. “The data we are presenting includes updates on DEXTENZA, which is commercially available to treat inflammation and pain associated ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and OTX-DED for the treatment of dry eye disease. All of the data being presented continue to demonstrate the breadth of our proprietary hydrogel technology and its potential to meet unmet needs in many areas of the ophthalmic space.”

Ocular Therapeutix Presentations at ASCRS:

DEXTENZA^® (Post-operative Ocular Inflammation and Pain):

• Title: Real-World Safety Analysis of an Intracanalicular Dexamethasone Insert Using the Intelligent Research in Site (IRIS) Registry
  
  Session Title: Medications (Preoperative, Postoperative, Intraoperative)
  
  Session Date/Times: Sunday, April 24, 2022 at 1:30 PM-1:35 PM ET
  
  Location: WEWCC, Level 1, 143C
  
  Presenter: Robert T Chang, MD, ABO
• Title: Real-World Characteristics of Patients Treated with Intracanalicular Dexamethasone Insert: An IRIS Registry Analysis 2019-2021
  
  Session Title: Medications (Preoperative, Postoperative, Intraoperative)
  
  Session Date/Times: Sunday, April 24, 2022 at 1:43 PM-1:48 PM ET
  
  Location: WEWCC, Level 1, 143C
  
  Presenter: Michael Mbagwu, MD

DEXTENZA (Allergic Conjunctivitis):

• Title: Effects of Punctal Occlusion on Ocular Itching and Conjunctival Redness in Subjects with Allergic Conjunctivitis
  
  Session Title: Ocular Surface Disease
  
  Session Date/Times: Monday, April 25, 2022 at 8:28 AM-8:33 AM ET
  
  Location: WEWCC, Level 1, 143A
  
  Presenter: Steven M. Silverstein, MD, FACS, ABO
• Title: Sustained 30 Day Effect of an Intracanalicular Dexamethasone Insert for Treating Ocular Itching Associated with Allergic Conjunctivitis
  
  Session Title: Ocular Surface Disease
  
  Session Date/Times: Monday, April 25, 2022 at 8:33 AM-8:38 AM ET
  
  Location: WEWCC, Level 1, 143A
  
  Presenter: Steven M. Silverstein, MD, FACS, ABO
• Title: Real-World Allergic Conjunctivitis Treatment Patterns of Eye Care Providers
  
  Session Title: Ocular Surface Disease
  
  Session Date/Times: Monday, April 25, 2022 at 8:51 AM-8:56 AM ET
  
  Location: WEWCC, Level 1, 143A
  
  Presenter: William C. Christie, MD, ABO
• Title: Patient Journey for Allergic Conjunctivitis and Initial Management
  
  Session Title: Ocular Surface Disease
  
  Session Date/Times: Monday, April 25, 2022 at 8:56 AM-9:01 AM ET
  
  Location: WEWCC, Level 1, 143A
  
  Presenter: Nandini Venkateswaran, MD, ABO

OTX-DED (dexamethasone intracanalicular insert) (Dry Eye Disease):

• Title: Safety and Efficacy of OTX-DED, an Intracanalicular Dexamethasone Insert, for the Treatment of Episodic Dry Eye Disease: A Phase 2 Study
  
  Session Title: Ocular Surface Disease III
  
  Session Date/Times: Saturday April 23, 2022 at 3:30 PM-3:35 PM ET
  
  Location: WEWCC, Level 1, 144B
  
  Presenter: Lisa M. Nijm, MD, JD, ABO

Investigator-Initiated Trials Presented at ASCRS:

• Title: Thermal Pulsation with or without Dexamethasone Intracanalicular Insert for Meibomian Gland Dysfunction: A Prospective, Masked Trial
  
  Session Title: ASCRS Electronic Posters (On-Demand)
  
  Presenter: Paul Cacchillo, MD
• Title: A Prospective, Randomized, Fellow Eye-Controlled Study of Post-Op Pain and Inflammation Control with DEXTENZA Insert Following SMILE
  
  Session Title: ASCRS Electronic Posters (On-Demand)
  
  Presenter: William F. Wiley, MD
• Title: Dexamethasone Intracanalicular Insert at the Time of Surgery VS 4 Days Before for Combined Phaco and Trabecular Microbypass Implantation
  
  Session Title: ASCRS Electronic Posters (On-Demand)
  
  Presenter: Damien Goldberg, MD
• Title: Prospective Study of Dexamethasone Ophthalmic Insert following Concomitant MIGS and Cataract Surgery
  
  Session Title: ASCRS LIVE Posters
  
  Session Date/Times: Sunday, April 24, 2022 at 3.10 PM-3:15 PM ET
  
  Location: Poster Pavilion, West Salon
  
  Presenter: Nicholas E. Tan, BA
• Title: Intracanalicular Dexamethasone for Post-Corneal Cross-Linking Inflammation and Pain
  
  Session Title: Keratoconus
  
  Session Date/Times: Saturday, April 23, 2022 at 8:00 AM-8:05 AM ET
  
  Location: WEWCC, Level 1, 143C
  
  Presenter: Alanna S. Nattis, DO
• Title: Efficacy of a Dexamethasone Intracanalicular Insert (OTX-DED), Compared to Loteprednol Suspension for the Treatment of Episodic Dry Eye
  
  Session Title: Ocular Surface Disease II
  
  Session Date/Times: Sunday, April 24, 2022 at 8:00 AM-8:05 AM ET
  
  Location: WEWCC, Level 1, 144A
  
  Presenter: Andrew J. Keyser, BSc
• Title: Comparing Intracanalicular and Topical Steroid Use in Patients Undergoing Pterygium Surgery
  
  Session Title: Ocular Surface Disease
  
  Session Date/Times: Monday, April 25, 2022 at 8:05 AM-8:10 AM ET
  
  Location: WEWCC, Level 1, 143A
  
  Presenter: Michelle K. Rhee, MD, ABO
• Title: Intracanalicular Dexamethasone Insert Versus Topical Steroid or Antihistamine Therapy for Treatment of Allergic Conjunctivitis
  
  Session Title: Ocular Surface Disease
  
  Session Date/Times: Monday, April 25, 2022 at 9:01 AM-9:06 AM ET
  
  Location: WEWCC, Level 1, 143A
  
  Presenter: Shani Reich, MD

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA^®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets include OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and other retinal diseases. OTX-TIC (travoprost intracameral implant) recently began a Phase 2 clinical trial to evaluate the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix has also completed Phase 2 clinical trials for OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease.

Forward-Looking Statements

Any statements in this press release about future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA^®, ReSure^® Sealant, or any of the Company’s product candidates; the commercial launch of, and the effectiveness of and amounts applicable to reimbursement codes for, DEXTENZA; the conduct of post-approval studies of and compliance with related labeling requirements for DEXTENZA and ReSure Sealant; the Company’s sales and marketing strategy; the development and regulatory status of the Company’s product candidates, such as the Company’s development of and prospects for approvability of OTX-CSI for the chronic treatment of dry eye disease, OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease, OTX-TIC for the treatment of primary open-angle glaucoma or ocular hypertension, and OTX-TKI for the treatment of retinal diseases including wet AMD; the ongoing development of the Company’s extended-delivery hydrogel depot technology; the size of potential markets for our product candidates; the potential utility of any of the Company’s product candidates; the potential benefits and future operations of Company collaborations, including any potential future costs or payments thereunder; projected net product revenue, in-market sales and other financial and operational metrics of DEXTENZA and ReSure Sealant; potential market sizes for indications targeted by the Company’s product candidates, if approved; the expected impact of the COVID-19 pandemic on the Company and its operations; the sufficiency of the Company’s cash resources and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, including the conduct of post-approval studies, the ability to successfully develop and commercialize products for the ophthalmology office setting, the ability to retain regulatory approval of DEXTENZA, ReSure Sealant or any product candidate that receives regulatory approval, the ability to maintain and the sufficiency of product, procedure and any other reimbursement codes for DEXTENZA, the initiation, timing, conduct and outcomes of clinical trials, whether clinical trial data such as the data reported in this release will be indicative of the results of subsequent clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company’s ability to enter into and perform its obligations under collaborations and the performance of its collaborators under such collaborations, the Company’s scientific approach and general development progress, the availability or commercial potential of the Company’s product candidates, the Company’s ability to meet supply demands, the Company’s ability to generate its projected net product revenue and in-market sales on the timeline expected, if at all, the sufficiency of cash resources, the Company’s existing indebtedness, the ability of the Company’s creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default, the severity and duration of the COVID-19 pandemic including its effect on the Company’s revenues and relevant regulatory authorities’ operations, any additional financing needs and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220414005882/en/